| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8684660 | Experimental Neurology | 2018 | 52 Pages |
Abstract
In summary, our data suggest that guanabenz and other GADD34 inhibitors could be used as therapeutic agents to boost parkin levels and thereby slow neurodegeneration in PD and other neurodegenerative conditions.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Xiaotian Sun, Pascaline Aimé, David Dai, Nagendran Ramalingam, John F. Crary, Robert E. Burke, Lloyd A. Greene, Oren A. Levy,